Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers

References

• Anderson S, Luffer-Atlas D, Knadler MP. (2009). Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243–256.
   PubMed Web of Science ®Google Scholar
• Aoki K, Kashiwagura Y, Horie T, Sato H, Tateno C, Ozawa N, Yoshizato K. (2006). Characterization of humanized liver from chimeric mice using coumarin as a human CYP2A6 and mouse CYP2A5 probe. Drug Metab Pharmacokinet 21:277–285.
   PubMed Web of Science ®Google Scholar
• Chen AA, Thomas DK, Ong LL, Schwartz RE, Golub TR, Bhatia SN. (2011). Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci USA 108:11842–11847.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–368.
   PubMed Web of Science ®Google Scholar
• De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, Olson K, Patel D, Wagner D, Yeager R, Serabjit-Singh C. (2011). Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464–475.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2008). Guidance for industry: safety testing of drug metabolites. FDA [Online] Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf. Accessed on 15 April 2011.
   Google Scholar
• Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H. (1991). Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metab Clin Exp 40:1213–1218.
   PubMed Web of Science ®Google Scholar
• Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, Gartung C. (2003). Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38:345–354.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–413.
   PubMed Web of Science ®Google Scholar
• Herman JR, Dethloff LA, McGuire EJ, Parker RF, Walsh KM, Gough AW, Masuda H, de la Iglesia FA. (2002). Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol Sci 68:226–236.
   PubMed Web of Science ®Google Scholar
• Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–903.
   PubMed Web of Science ®Google Scholar
• Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. (2008). CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:2429–2433.
   PubMed Web of Science ®Google Scholar
• Inoue T, Sugihara K, Ohshita H, Horie T, Kitamura S, Ohta S. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153–160.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. ICH [Online] Available at: http://www.ich.org/products/guidelines/safety/safety-single/article/guidance-on-nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-author.html. Accessed on 15 April 2011.
   Google Scholar
• Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. (1996). Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630–1641.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Campbell LK, Campbell RK. (1998). Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 32:337–348.
   PubMed Web of Science ®Google Scholar
• Kakuni M, Morita M, Katoh Y, Nakajima M, Tateno C, Yokoi T. (2011). Troglitazone-induced liver injury in chimeric mice with humanized liver. Abstract #510 Society of Toxicology Annual Meeting [Online] Available at: http://www.phoenixbio.co.jp/introduce/newsrelease/jqunv8000000183b-att/jqunv8000000184m.pdf. Accessed on 15 August 2011
   Google Scholar
• Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, Usui T. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223–235.
   PubMed Web of Science ®Google Scholar
• Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA. (2001). Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62–70.
   PubMed Web of Science ®Google Scholar
• Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145–157.
   PubMed Web of Science ®Google Scholar
• Kawai K, Kawasaki-Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T, Yoshioka T, Komai T, Nakamura K. (1997). Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47:356–368.
   PubMed Web of Science ®Google Scholar
• Kawai K, Tsurut, F, Iwabuchi H, Ishikawa M, Haruyama H, Ikenaga H, Ikeda T, Nakamura, K. (2000). Disposition and metabolism of the oral antidiabetyic drug troglitazone in monkeys. Xenobio Metabol and Dispos 15:89–100.
   Google Scholar
• Kitamura S, Nitta K, Tayama Y, Tanoue C, Sugihara K, Inoue T, Horie T, Ohta S. (2008). Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202–1205.
   PubMed Web of Science ®Google Scholar
• Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. (2000). Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272–276.
   PubMed Web of Science ®Google Scholar
• Li M, Wang W, Soroka CJ, Mennone A, Harry K, Weinman EJ, Boyer JL. (2010). NHERF-1 binds to Mrp2 and regulates hepatic Mrp2 expression and function. J Biol Chem 285:19299–19307.
   PubMedGoogle Scholar
• Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, Koup JR. (1999a). Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 39:920–926.
   PubMed Web of Science ®Google Scholar
• Loi CM, Young M, Randinitis E, Vassos A, Koup JR. (1999b). Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91–104.
   PubMed Web of Science ®Google Scholar
• Lootens L, Meuleman P, Leroux-Roels G, Van Eenoo P. (2011). Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. Steroid Biochem Mol Biol 127:374–381.
   PubMed Web of Science ®Google Scholar
• Milkiewicz P, Chilton AP, Hubscher SG, Elias E. (2003). Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). Gut 52:300–303.
   PubMed Web of Science ®Google Scholar
• Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, Yokoi T. (2007). Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533–538.
   PubMed Web of Science ®Google Scholar
• Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA. (2011). Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 10:292–306.
   PubMed Web of Science ®Google Scholar
• Prabhu S, Fackett A, Lloyd S, McClellan HA, Terrell CM, Silber PM, Li AP. (2002). Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem Biol Interact 142:83–97.
   PubMed Web of Science ®Google Scholar
• Smith MT. (2003). Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16:679–687.
   PubMed Web of Science ®Google Scholar
• Strom SC, Davila J, Grompe M. (2010). Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491–509.
   PubMedGoogle Scholar
• Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–912.
   PubMed Web of Science ®Google Scholar
• Tettey JN, Maggs JL, Rapeport WG, Pirmohamed M, Park BK. (2001). Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 14:965–974.
   PubMed Web of Science ®Google Scholar
• Yamasaki C, Kataoka M, Kato Y, Kakuni M, Usuda S, Ohzone Y, Matsuda S, Adachi Y, Ninomiya S, Itamoto T, Asahara T, Yoshizato K, Tateno C. (2010). In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 25:539–550.
   PubMed Web of Science ®Google Scholar
• Yano K, Sekine S, Nemoto K, Fuwa T, Horie T. (2010). The effect of dimerumic acid on LPS-induced downregulation of Mrp2 in the rat. Biochem Pharmacol 80:533–539.
   PubMed Web of Science ®Google Scholar
• Yoshizato K, Tateno C. (2009). In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 5:1435–1446.
   PubMed Web of Science ®Google Scholar